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Abstract: The occurrence of Candida albicans device-associated infections is tightly correlated to the 
ability of this fungus to form biofilms. The presence of this three-dimensional structure protects cells 
from host defenses, and significantly increases their resistance to antifungal agents. Lipopeptide 
biosurfactants are microbial products with interesting antibacterial, antifungal and anti-adhesive 
properties. Aim of the present study was to investigate a possible synergistic effect of lipopeptide 
AC7BS in combination with amphotericin B or fluconazole against C. albicans planktonic cells, 
biofilm formation and 24 h-old biofilms on medical-grade silicone elastomer disks, in simulated 
physiological conditions. In co-incubation experiments, AC7BS alone was not effective. However, the 
combination of AC7BS with the antifungal compounds resulted in a synergistic increase in the efficacy 
of the drugs against planktonic cells and biofilm, leading to a reduction of MICs and SMICs50. In 
pre-coating conditions, amphotericin B alone and AC7BS alone significantly inhibited C. albicans 
biofilms. When the two molecules were tested in association, a synergistic effect was observed on 
different phases of biofilm formation and a lower SMIC50 was detected. The observed synergism could 
be related to the combination of the AC7BS anti-adhesive activity and the AMB antifungal effect, but 
also to the ability of the biosurfactant to affect membranes, thus facilitating AMB entry in the cells. 
These results suggest that AC7BS can be considered a potential inhibitor of C. albicans biofilm on 
medical insertional materials and its use as coating agent may potentiate the effect of antifungal 
compounds such as AMB, when applied in combination.  
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1. Introduction  
Biofilms are communities of microorganisms attached to biotic and abiotic surfaces surrounded 
by an extracellular polymeric substance (EPS) and often involved in chronic infections and medical 
device contamination [1,2]. Host defense systems typically eliminate transient bacterial contamination, 
however, the presence of biofilm may protect the microorganisms, and significantly reduce its 
susceptibility to antimicrobial agents [3,4].  
The dimorphic yeast Candida albicans is the fungal species most frequently isolated from 
medical devices, such as catheters, heart valves and urinary devices [5,6]. When host immune 
functions are decreased or the competitive commensal flora is perturbed, C. albicans can be 
responsible for superficial or life threatening systemic infections [7]. A study performed in the United 
States showed that C. albicans infections are the fourth most common hospital acquired systemic 
infections with a high mortality rate [8]. Risk factors for infection include neutropenia, damage of 
mucosae and the use of broad-spectrum antimicrobials. Moreover, the application of central venous 
catheters represents a cause of systemic infections because of direct contact with the bloodstream [9].  
A major problem in the eradication of nosocomial C. albicans infections is the resistance of the 
biofilms to established antifungal agents like polyenes and azoles. The resistance is found to be 
multifactorial. Ramage et al. [10] describe the resistance mechanisms, which include general 
physiological state of sessile cells, cell density, over-expression of drug targets, efflux pump mediated 
resistance, extracellular matrix, persister cells and tolerance against stress. In almost all the cases, the 
presence of C. albicans biofilms often requires implant removal, with significant increase of morbidity, 
mortality and hospital costs [11]. As frequent replacement is uncomfortable, costly, time consuming 
and may lead to damage of the cellular tissue in patients, alternative approaches are highly desirable. 
Current strategies to prevent biofilm formation provide medical devices coated with antimicrobials [1]. 
From this point of view, it could be useful to increase the efficacy of known antifungal drugs.  
Biosurfactants, amphiphilic metabolites produced by a wide group of microorganisms, can 
represent a useful approach to counteract biofilms. In particular, lipopeptides exhibit interesting 
biological properties such as high surface activity and antimicrobial potential [12]. We previously 
demonstrated that the coating of silicone elastomer disks with a lipopeptide biosurfactant from 
Bacillus subtilis AC7 led to the reduction of C. albicans biofilm formation [13]. Other studies on 
lipopeptides demonstrated their efficacy against Escherichia coli CFT073 pre-formed biofilms in 
combination with antibiotics [14] or silver [15]. In particular, results indicated that the V9T14 
lipopeptide alone was not able to remove pre-formed biofilms but its association with antibiotics led to 
a synergistic increase in their efficacy up to a total eradication of biofilm, in some combinations [14]. 
In addition, the activity of silver was synergistically enhanced by the presence of V9T14 lipopeptide, 
leading to a significant reduction of the amount of AgNO3 used and to an increase of its antimicrobial 
activity [15]. 
In the present study, the efficacy of AC7 lipopeptide biosurfactant in association with two 
clinically used antifungal agents, amphotericin B and fluconazole, against C. albicans planktonic cells 
and biofilm formation was assessed on silicone elastomer, with the aim to identify a synergistic 
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2. Materials and Methods 
2.1. Strains and growth condition 
The biosurfactant-producing strain Bacillus subtilis AC7, isolated from the inside of stems of 
Robinia pseudoacacia, was cultivated in Luria–Bertani (LB) broth (Sigma-Aldrich) and stored at 
–80 °C in the same medium supplemented with 25% glycerol. For biofilm assays, Candida albicans  
40 (DSM 29204), a wild strain clinically isolated from a central venous catheter (courtesy of  
Hospital ‘‘Maggiore della Carità’’, Novara, Italy), was cultivated in Yeast Nitrogen Base        
broth (Sigma-Aldrich) with 50 mmol l–1 dextrose (Biolife Italiana Srl, Milan, Italy) (YNBD) and 
stored at –80 °C in sabouraud dextrose broth (Sigma-Aldrich) supplemented with 25% glycerol. 
2.2. Biosurfactant production 
A loop of B. subtilis AC7, from a LB agar overnight culture, was inoculated into 20 ml of LB 
broth and incubated at 28 °C for 4 h at 140 rev min–1. Two milliliters of the seed culture were 
inoculated in 500 ml of the same medium, and incubated for 24 h at the previously described growth 
conditions. AC7BS was extracted according to the method described by Rivardo et al. [16]. 
2.3. Medical-grade silicone elastomeric disks preparation 
Two different sizes of medical-grade silicone elastomeric disks (SEDs) (TECNOEXTR S.r.l., 
Italy) were used: 5 mm in diameter and 1.5 mm in thickness for experiments in 96-well plates, and   
10 mm in diameter and 1.5 mm in thickness for experiments in 24-well plates. Cleaning and 
sterilisation of SEDs were carried out as described by Busscher et al. [17]. Briefly, disks were 
immersed in 200 ml of distilled water supplemented with 1.4% (v/v) of RBSTM 50         
solution (Sigma-Aldrich), sonicated for 5 min at 60 kHz using Elma S30H (Elmasonic, VWR 
International) and rinsed twice in 1 l of MilliQ water. Then, disks were submerged in 20 ml of 
methanol (99%) (Sigma-Aldrich), rinsed twice and autoclaved for 15 min at 121 °C. 
2.4. Antifungal activity on planktonic cells 
The antifungal activity of AMB (Sigma-aldrich), FLC (Sigma-aldrich) and AC7BS towards 
planktonic cells of C. albicans 40 was assessed according to EUCAST guidelines [18]. Briefly, 100 µl 
AC7BS 2× (2 mg ml–1 in phosphate buffered saline-PBS), AMB 2× (0.25, 0.5, 1 µg ml–1 in PBS) or 
FLC 2× (0.25, 0.5, 1 µg ml–1 in PBS) were added in a 96-well plate (Bioster). When the joint activity of 
AC7BS and the antifungal drugs was evaluated, 50 µl AC7BS 4× (4 mg ml–1 in PBS) were mixed with 
50 µl of AMB 4× (0.5, 1, 2 µg ml–1 in PBS) or FLC 4× (0.5, 1, 2 µg ml–1 in PBS). In control wells (no 
biosurfactant or antifungal drugs added), 100 µl of sterile PBS were used. A standardized C. albicans 
suspension at the concentration of 1–5 × 105 Colony Forming Units (CFU ml–1) was prepared in sterile 
double-strength Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich) buffered 
with 3-(N-morpholino)propanesulfonic acid buffer (MOPS) (Sigma-Aldrich) and supplemented with 
D-glucose (2% final concentration), pH 7.0. One hundred microliters of this suspension were added to 
test wells, to obtain final concentrations of 1 mg ml–1 AC7 BS, 0.125, 0.25, 0.5 µg ml–1 AMB and 
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0.125, 0.25, 0.5 µg ml–1 FLC, and to control wells. Corresponding blank wells (without planktonic 
cells) were also prepared. The plate was incubated at 37 °C for 24 h in static conditions. Finally, OD450 
was measured in each well using an Ultramark Microplate Imaging System (Bio-Rad). The data were 
normalized with respect to the value of the corresponding blank wells. The percentage of inhibition in 
each well, compared to control wells (containing disks not treated with biosurfactant or AMB), was 
determined as: 
[1–(ODtreat/ODctrl)] × 100         (1) 
Where: ODtreat, optical density of treated samples; ODctrl, optical density of controls. 
The minimal inhibitory concentration of AMB was defined as the lowest concentration leading to 
a growth inhibition ≥ 90% in comparison to control (MIC90), while that of FLC as the lowest 
concentration giving inhibition ≥ 50% (MIC50). Assays were carried out in triplicate, and repeated in 
two different days. 
2.5. Anti-biofilm assays 
2.5.1. Co-incubation  
The susceptibility of C. albicans 40 sessile cells to AMB, FLC and AC7BS was performed in 
96-well plates as described by Nweze et al. [19] with some modification. SEDs were pre-coated with  
3 ml fetal bovine serum (FBS) (Sigma-Aldrich) in 12-well plates (eight disks per well) at 37 °C for  
24 h at 140 rev min–1 and, then, inoculated with 4 ml standardized fungal suspension containing         
1 × 107 CFU ml–1 in PBS. 
To evaluate the susceptibility of C. albicans in the intermediate phase of biofilm formation, after 
1.5 h at 37 °C (adhesion phase), SEDs were transferred in a 96-well plate (Bioster) and incubated in 
200 µl YNBD supplemented with AC7BS alone (final concentration 1 mg ml–1) or AMB (final 
concentrations 0.5, 1, 2 µg ml–1) and FLC (final concentrations 64, 128, 256 µg ml–1) alone or in 
combination with AC7BS. Control wells consisted of YNBD supplemented by an equal volume of the 
antifungal/AC7BS diluent (i.e. PBS). The plates were incubated at 37 °C for 24 h for biofilm growth. 
Furthermore, the effect of AC7BS, AMB and FLC alone or in combination was also evaluated on 
24 h-old biofilms (mature phase). In this case, C. albicans biofilms were grown for 24 h at 37 °C using 
the protocol described above. Subsequently, 200 µl YNBD supplemented with AC7BS (final 
concentration 1 mg ml–1), AMB (final concentrations 2, 4, 8 µg ml–1) and FLC (final concentrations 64, 
128, 256 µg ml–1) alone or in combination were added and the plates incubated for additional 24 h at 
37 °C. Control wells consisted of YNBD supplemented by an equal volume of the antifungal/AC7BS 
diluent (i.e. PBS). 
2.5.2. Pre-coating  
C. albicans biofilms on AC7BS pre-coated SEDs were prepared as described by Ceresa et al. [13]. 
Briefly, SEDs were dipped into 1 ml of a 2 mg ml–1 AC7BS solution or in PBS only and incubated at 
37 °C for 24 h at 140 rpm. SEDs were then placed in a new 24-well plate and 1 ml of standardized C. 
albicans suspension at the concentration of 1 × 107 CFU ml–1 in PBS + 10% FBS was added in each 
well (t = 0). After 1.5 h incubation, the disks were transferred into 1 ml YNBD + 10% FBS and 
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incubated at 37 °C for 24 h at 100 rpm.  
The activity of AMB was evaluated at different times of biofilm formation on SEDs pre-coated or 
not with AC7BS. In particular, the antifungal drug was added both to the standardized fungal 
suspensions at t = 0 and to the growth medium at t = 1.5 h to evaluate its efficacy on both adhesion and 
intermediate phase of biofilm formation, at the concentrations of 0.125, 0.25, 0.5 µg ml–1 (pre-coating 
type 1), or only to the growth medium at t = 1.5 h, to test its activity in the intermediate phase only, at 
the concentrations of 0.5, 1, 2 µg ml–1 (pre-coating type 2). Control wells (containing disks not treated 
with biosurfactant or AMB) and AC7BS alone wells (containing AC7BS pre-coated disks) consisted 
of 1 ml YNBD + 10% FBS, supplemented by an equal volume of the antifungal diluent (i.e PBS). 
Furthermore, the effect of AMB alone or in combination with AC7BS was also evaluated on   
24 h-old biofilms (pre coating type 3). Biofilms were formed for 24 h at 37 °C by using the protocol 
described above. Afterwards, 1 ml YNBD + 10% FBS supplemented with AMB at the final 
concentrations of 2, 4, 8 µg ml–1 was added and the plate incubated for additional 24 h at 37 °C. 
Control and AC7BS alone wells consisted of YNBD + 10% FBS, supplemented by an equal volume of 
the antifungal diluent (i.e. PBS). 
2.6. Quantification of biofilm  
The quantification of C. albicans 40 biofilms was performed by the {2,3 
bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide} (XTT, 
Sigma-Aldrich) colorimetric assay. A working solution was prepared by adding 12.5 µl XTT   
solution (1 mg ml–1) and 1 µl of 1 mmol l–1 menadione solution to 1 ml PBS. Biofilm growth medium 
was carefully removed by aspiration and replaced with XTT working solution. The plates were 
covered with aluminum foil and incubated for 5 h at 37 °C. Blank wells containing  disks without 
biofilm were also included. Afterwards, the supernatant was carefully transferred into a new plate and 
the absorbance was measured at 490 nm (OD490) using an Ultramark Microplate Imaging      
System (Bio-Rad). Each tested condition was carried out in triplicate and experiments were repeated at 
least two times in different days. The data were normalized with respect to the blank values. The 
percentage of inhibition in each well, compared to control wells, was determined as indicated 
previously.  
The sessile minimal inhibitory concentration (SMIC) of AMB and FLC was defined as the lowest 
concentration leading to a metabolic activity inhibition ≥ 50% compared to control wells (SMIC50). 
2.7. Evaluation of synergism  
Synergism is generally defined as the interaction between two or more molecules whose effect, in 
association, is greater than the combination of the effects of the individual compounds. Usually, the 
combination under consideration consists in an additive effect. However, if the effect is a   
percentage (in our case, a survival percentage), this is not additive but multiplicative; the combination 
of the effects of two compounds (assuming they act independently) is, thus, the product of the 
percentages. Synergy, in this context, amounts to say that the survival percentage due to the two 
compounds acting simultaneously is less than the product of survival percentages due to the two 
compounds by themselves.  
In this work, the effect (E) of a treatment (T) (i.e. survival) is calculated as OD*T = ODT/ODctrl.  
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The synergism is evaluated by comparing the multiplicative effect x1 = OD*(AC7) × OD*(antifungal) 
with the experimental effect x2 = OD*(AC7 & antifungal agent). If x1 > x2 in a statistical significant way, then 
we are in presence of synergism.  
2.8. Statistical analysis 
Statistical analysis and graphs were elaborated by means of the statistical program R,3.1.2. (R 
Development Core Team, http//www.R-project.org). Two-way ANOVA was performed to investigate 
the effect of AC7BS and antifungal agents alone or in combination on C. albicans planktonic or sessile 
cells both in co-incubation and pre-coating conditions. Results were considered to be statistically 
significant when P < 5 × 10–2. 
3. Results 
3.1. Joint activity of amphotericin B, fluconazole and lipopeptide biosurfactant AC7 on planktonic 
cells of Candida albicans 40 
To define a possible joint activity against C. albicans 40 planktonic cells, the two antifungal 
agents were tested in association with the lipopeptide biosurfactant AC7 (AC7BS) at two sub-MIC 
concentrations (0.125 µg ml–1, 0.25 µg ml–1) and at the MIC (0.5 µg ml–1). These concentrations were 
chosen based on previously calculated MIC90 for AMB and MIC50 for FLC (data not shown).  
AC7BS was tested at the concentration of 1 mg ml–1. The optical density at 450 nm (OD450) of 
planktonic cells in co-incubation with or without AC7BS is displayed as a function of the 
concentration of AMB or FLC (Figure 1).  
 
Figure 1. Dose-response (OD) curves of antifungal agents (AMB or FLC) alone or in 
association with AC7BS (1 mg ml–1) on Candida albicans 40 planktonic (A, D) or sessile cells 
in the intermediate (B, E) and mature (C, F) phases of biofilm formation, in co-incubation 
condition. Dots (6 for each concentration) represent the experimental data of dose-response 
curve. 
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For AMB, the net OD450 value of control (no BS or antifungal drug added) was 1.103  0.007 and 
decreased to 0.859  0.005, 0.719  0.005 and 0.022  0.001 when planktonic cells were treated with 
0.125, 0.25 and 0.5 µg ml–1 AMB, respectively. Cells co-incubated with AC7BS alone showed a net 
OD450 value of 1.105  0.005 that decreased to 0.180  0.001, 0.039  0.008 and 0.018  0.001 when 
the biosurfactant was associated with the three concentrations of AMB (Figure 1A).  
For FLC, the net OD450 value of control was 1.108  0.001 and decreased to 1.107  0.002,  
0.702  0.001 and 0.231  0.002 when planktonic cells were treated with 0.125, 0.25 and 0.5 µg ml–1 
FLC, respectively. Cells co-incubated with AC7BS showed a net OD450 value of 1.108  0.002 that 
decreased to 0.864  0.002, 0.432  0.003 and 0.064  0.003 when the biosurfactant was associated 
with the tree concentrations of FLC (Figure 1D).  
According to ANOVA analysis, the survival of C. albicans 40 planktonic cells was significantly 
dependent on the concentration of antifungal agents (P < 1 × 10–14) and on the type of       
treatment (P < 1 × 10–5) both for AMB and FLC.  
The percentage of inhibition of C. albicans 40 planktonic cells are reported in Table 1. With 
respect to controls, the growth of C. albicans 40 planktonic cells was significantly inhibited up to  
98.0% by 0.5 µg ml–1 AMB and up to 79.1% by 0.5 µg ml–1 FLC. AC7BS alone resulted to be 
ineffective, suggesting that biosurfactant had no antifungal activity. The joint application of AC7BS 
and the antifungals significantly reduced Candida growth up to 98.4% at 0.5 µg ml–1 AMB and up to 
94.3% at 0.5 µg ml–1 FLC.  
Table 1. Inhibition of Candida albicans 40 planktonic and sessile cells by treatment with 
antifungal drugs alone or in combination with AC7BS in co-incubation conditions. 
 Antifungal Concentration (µg ml–1) Percentage of inhibition (%)  Antifungal AC7BS&antifungal 
Planktonic cells AMB 0.125 22.2 83.7 
  0.25 34.7 96.5 
  0.5 98.0 98.4 
 FLC 0.125  22.0 
  0.25 36.5 61.0 
  0.5 79.1 94.3 
Sessile cells intermediate phase AMB 0.5 20.0 61.2 
  1 52.8 93.0 
  2 75.7 99.6 
 FLC 64 23.7 46.3 
  128 22.0 46.0 
  256 23.8 47.4 
Sessile cells mature phase AMB 2 37.9 50.0 
  4 54.5 67.3 
  8 61.8 74.3 
 FLC 64 6.0 7.0 
  128 6.0 7.0 
  256 6.0 7.0 
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Furthermore, in both cases, the MIC value of each antibiotic was decreased by the presence of 
AC7BS from 0.5 µg ml–1 to 0.25 µg ml–1. 
Figure 2 shows the experimental and multiplicative effect of AC7BS and the antifungal drugs 
against C. albicans 40 planktonic cells, calculated as described in the Materials and Methods section. 
In particular, when the two sub-MIC concentrations of AMB (Figure 2A) or the three concentrations of 
FLC (Figure 2D) were associated with AC7BS, the experimental effect OD*(AC7 & antifungal) was less 
than the multiplicative effect OD*(AC7) × OD*(antifungal), indicating a strong synergistic association. 
ANOVA analysis, confirms synergy (P < 1 × 10–5) and its dependence on concentrations (P < 1 × 10–14). 
3.2. Anti-biofilm assays 
3.2.1. Co-incubation  
The two antifungal agents were tested in association with AC7BS to evaluate a possible joint 
activity against C. albicans 40 sessile cells at different phases of biofilm formation. AMB was applied 
at a sub-SMIC50 concentration (0.5 µg ml–1), at the SMIC50 (1 µg ml–1) and at 2 µg ml–1 in the 
intermediate phase whereas at 2 µg ml–1 (sub-SMIC50), 4 µg ml–1 (SMIC50) and 8 µg ml–1 in the mature 
phase of biofilm formation. FLC was tested in both cases at three sub-SMIC50 concentrations (64, 128, 
256 µg ml–1). These concentrations were chosen based on previously calculated SMICs50 for AMB and 
FLC on intermediate and mature phases of biofilm formation (data not shown). AC7BS was used at the 
concentration of 1 mg ml–1. The metabolic activity (OD490) of sessile cells in co-incubation with or 
without AC7BS is shown as a function of the concentration of AMB or FLC (Figure 1).  
For AMB, in the intermediate phase of biofilm formation, the OD490 value of control was   
0.198  0.006 and decreased to 0.158  0.001, 0.093  0.005 and 0.048  0.006 when sessile cells 
were treated with respectively 0.5, 1, 2 µg ml–1AMB. When cells were co-incubated with AC7BS, the 
value was 0.188  0.003 and decreased to 0.077  0.006, 0.014  0.002 and 0.001  0.001 when the 
two molecules were associated (Figure 1B). In the mature phase, the OD490 value of control was  
0.173  0.004 and decreased to 0.108  0.003, 0.079  0.008 and 0.066  0.004 when sessile cells 
were treated with 2, 4, 8 µg ml–1 AMB. In the presence of AC7BS, the OD490 value was 0.166  0.005 
and decreased to 0.087  0.004, 0.057  0.004 and 0.045  0.006 when AC7BS was associated with 
AMB (Figure 1C).  
For FLC, in the intermediate phase of biofilm formation, the OD490 value of control was    
0.201  0.005 and decreased to a mean value of 0.155  0.007 at the three tested concentrations. 
Sessile cells co-incubated with AC7BS showed a value of 0.190  0.002 that decreased to a mean 
value of 0.108  0.005 when biosurfactant was associated with FLC (Figure 1E). In the mature phase, 
the value of control was 0.171  0.004 and decreased to a mean value of 0.160  0.005 in the presence 
of FLC. Sessile cells co-incubated with AC7BS showed a value of 0.165  0.007 that decreased to a 
mean value of 0.159  0.003 when biosurfactant was associated with FLC (Figure 1F).  
In the intermediate phase, sessile cells survival was significantly dependent on the concentration 
of antifungal agent (P < 1 × 10–6) and on the type of treatment (P < 1 × 10–6) both for AMB and FLC 
whereas on 24 h-old biofilms, it was significantly dependent on the concentration of antifungal   
agent (P < 1 × 10–3) and on the type of treatment (P = 1 × 10–2) only in the case AMB. 
The percentages of inhibition of C. albicans 40 sessile cells are reported in Table 2. In the 
intermediate and mature phases, the metabolic activity of cells co-incubated with AC7BS was 
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comparable to that of control (no BS or antifungal drug added) indicating that biosurfactant had no 
antifungal activity on biofilm. AMB significantly counteracted C. albicans 40 biofilm in the 
intermediate phase up to 75.7% at 2 µg ml–1 whereas significantly reduced 24 h-old biofilm up to   
61.8% at 8 µg ml–1. Regarding FLC, in the intermediate phase, C. albicans 40 biofilm formation was 
significantly inhibited of about 23% at 64, 128, 256 µg ml–1 but no relevant activity on 24 h-old 
biofilm was detected. The simultaneous use of AC7BS and AMB significantly inhibited C. albicans 40 
intermediate phase biofilm up to 99.6% (at 2 µg ml–1) whereas significantly reduced 24 h-old biofilms 
up to 74.3% (at 8 µg ml–1). The simultaneous use of AC7BS and FLC at all the tested concentrations 
significantly inhibited C. albicans 40 in the intermediate phase of biofilm formation of about 46.6% 
whereas no joint activity on 24 h-old biofilms was observed. 
Furthermore, the SMIC50 values of AMB were decreased by the presence of AC7BS from      
1 µg ml–1 to 0,5 µg ml–1 in the intermediate phase and from 4 µg ml–1 to 2 µg ml–1 in the mature phase 
of biofilm formation. 
The synergistic activity of AC7BS and the antifungal drugs against C. albicans 40 biofilm 
formation was evaluated (Figure 2). In the intermediate phase, both for AMB and FLC, the occurrence 
of synergism is visualized by the higher position of the blue curve in comparison to the red      
curve (Figure 2B and Figure 2E). In the mature phase (Figure 2C and 2F), the synergism of AC7BS 
and antifungal drugs was observed only in the case of AMB (Figure 2C). Globally, the synergistic 
association and its dependence on the concentration of antifungal agents are significantly confirmed by 
ANOVA analysis (P < 1 × 10–2 and P < 1 × 10–14, respectively). 
 
Figure 2. Synergism of antifungal drugs (AMB and FLC) and AC7BS (1 mg ml–1) against 
Candida albicans 40 planktonic (A, D) and sessile cells on intermediate (B, E) and mature (C, 
F) phases of biofilm formation in co-incubation conditions. Dots (6 for each concentration) 
represent the experimental data of dose-response curve. 
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3.2.2. Pre-coating  
The antifungal effect of AMB, the anti-adhesive properties of AC7BS and the combination of the 
two activities (AMB&AC7BS) were evaluated against C. albicans 40 biofilm formation in pre-coating 
conditions. In particular, the activity of AMB (alone or in combination with AC7BS pre-coating) was 
evaluated in three different experimental settings: AMB added at time 0 to the fungal suspension and at 
time 1.5 h to the growth medium, at the concentrations of 0.125, 0.25, 0.5 µg ml–1 (pre-coating type 1); 
AMB added only at time 1.5 h to the growth medium, at the concentrations of 0.5, 1,         
2 µg ml–1 (pre-coating type 2); AMB added at time 24 h to the growth medium, at 2, 4,         
8 µg ml–1 (pre-coating type 3). These concentrations were again chosen based on the previously 
calculated MICs and SMICs for AMB on planktonic and sessile Candida cells. 
In Figure 3, the metabolic activity (OD490) of C. albicans 40 in biofilm formation on silicone 
elastomeric disks pre-coated with or without AC7BS is shown as a function of the concentration of 
AMB. 
 
Figure 3. Dose-response (OD) curves of AMB alone or in association with AC7BS (2 mg ml–1) 
pre-coating on Candida albicans 40 biofilm formation on silicone. In pre-coating type 1, AMB 
was added at time 0 and at time 1.5 h (A); in pre-coating type 2, AMB was added only at time 
1.5 h (B) and in pre-coating type 3, AMB was added at time 24 h (C). Dots (6 for each 
concentration) represent the experimental data of dose-response curve. 
In pre-coating type 1, the OD490 value of control was 0.102  0.003 and decreased to       
0.100  0.007, 0.090  0.008 and 0.070  0.007 when cells were treated with respectively 0.125, 0.25, 
0.5 µg ml–1AMB. When cells were treated with AC7BS the value was 0.047  0.010 and decreased to   
0.039  0.012, 0.029  0.018 and 0.005  0.003 when AC7BS were associated with the three 
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concentrations of AMB (Figure 3A).  
In pre-coating type 2, the OD490 value of control was 0.109  0.011 and decreased to       
0.065  0.006, 0.043  0.009 and 0.022  0.007 when cells were treated with respectively 0.5, 1,     
2 µg ml–1AMB. When cells were treated with AC7BS the value was 0.052  0.011 and decreased up to  
0.02  0.002 when AC7BS was associated with AMB at 2 µg ml–1 (Figure 3B).  
In pre-coating type 3, the OD490 value of control was 0.105  0.014 and decreased to       
0.072  0.011, 0.052  0.007 and 0.042  0.010 when cells were treated with respectively 2, 4,      
8 µg ml-1AMB. When cells were treated with AC7BS the value was 0.061  0.009 and decreased to   
0.025  0.004, 0.010  0.001 and 0.003  0.002 when AC7BS was associated with the three 
concentrations of AMB (Figure 3C).  
Globally, according to ANOVA analysis, C. albicans 40 biofilm formation is significantly 
dependent on the concentration of AMB (P = 1 × 10–14), on the type of treatment (P = 1 × 10–10) and on 
the pre-coating type (P = 1 × 10–15). 
The complete set of percentages of inhibition in pre-coating assays is reported in Table 2. 
In pre-coating type 1, with respect to controls, AC7BS significantly reduced C. albicans 40 
sessile cell of 53.7%. AMB significantly killed cells up to 31.4% at 0.5 µg ml–1, whereas its 
simultaneous use with AC7BS up to 94.7% (at 0.5 µg ml–1). In addition, in the presence of AC7BS, the 
SMIC50 value was achieved at 0.125 µg ml–1. 
In pre-coating type 2, with respect to controls, AC7BS reduced C. albicans 40 sessile cells of  
52.4% whereas AMB up to 79.4% at 2 µg ml–1. The use of the two molecules together significantly 
inhibited C. albicans 40 up to 98.2% at 2 µg ml–1. In addition, in the presence of AC7BS, the SMIC90 
value of AMB was reached at 0.5 µg ml–1. 
In pre-coating type 3, with respect to controls, AC7BS significantly reduced 24 h-old biofilms of 
41.7% whereas AMB of 60.2% at 8 µg ml–1. The joint application of AC7BS and AMB significantly 
inhibited 24 h-old biofilms up to 97.0% at 8 µg ml–1. Furthermore, a decrease of the SMIC50 value, 
from 4 µg ml–1 to 2 µg ml–1 was achieved. 
Table 2. Inhibition of Candida albicans 40 biofilm formation in pre-coating assays. 
 AMB (µg ml–1) Percentage of inhibition (%)  AC7BS AMB AC7BS&AMB 
Pre-coating type 1 0.0 53.7   
 0.125   61.9 
 0.25  11.5 71.9 
 0.5  31.4 94.7 
Pre-coating type 2 0.0 52.4   
 0.5  40.4 96.9 
 1  60.5 98.2 
 2  79.4 98.2 
Pre-coating type 3 0.0 41.7   
 2  31.9 75.9 
 4  50.4 90.3 
 8  60.2 97.0 
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The activity obtained by the association of AC7BS and AMB in the pre-coating assays was 
graphically expressed in Figure 4.  
 
Figure 4. Synergism of AMB and AC7BS (2 mg ml–1) pre-coating against Candida albicans 
40 biofilm formation on silicone. Pre-coating type 1 (A), pre-coating type 2 (B) and 
pre-coating type 3 (C). In pre-coating type 1, AMB was added at time 0 and at time 1.5 h (A); 
in pre-coating type 2, AMB was added only at time 1.5 h (B) and in pre-coating type 3, AMB 
was added at time 24 h (C). Dots (6 for each concentration) represent the experimental data of 
dose-response curve. 
An interesting synergistic association was reported in all the three type of experiments, confirmed 
by the higher position of OD*(AC7BS) × OD*(AMB) curve with respect to OD*(AC7BS & AMB) curve. 
ANOVA analysis confirms synergy (P < 1 × 10–3) and its dependence on concentration (P < 1 × 10–7).  
4. Discussion 
Candida species are involved in Candidiasis, the most common opportunistic yeast infection, and 
Candida albicans, the most prevalent, is responsible of approximately 50–90% of cases [20]. C. 
albicans pathogenesis is closely associated to its ability to growth as biofilms, structured cell 
communities embedded in extracellular matrix, that protect the microorganism from host defences and 
reduce significantly its susceptibility to antifungal agents [21]. Amphotericin B and fluconazole 
represent antifungal agents of choice in the treatment of serious Candida infections [22]. The 
interaction of amphotericin B with ergosterol results in pores formation, surface adsorption and 
ergosterol extraction from plasma membranes leading to membrane damage and rapid fungal cell 
death [23]. Fluconazole interferes with the ergosterol synthesis preventing the conversion of lanosterol 
to ergosterol by the inhibition of the fungal cytochrome P450 enzyme 14α-demethylase [24]. Despite 
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the presence of more effective antifungal agents, active on both planktonic and sessile cells such as 
AMB and echinocandins, fluconazole is still widely used in the clinic because of its efficacy and low 
toxicity. Various approaches have been recently proposed to increase the susceptibility of C. albicans 
to fluconazole, such as its combined use with different classes of non-antifungal agents that overcome 
fungal resistance or enhance antifungal activity [25].  
In the presence of biofilm, antifungal drugs are generally less effective or, in some cases, even 
ineffective. To overcome this serious clinical problem, novel strategies in preventing biofilm 
development are beginning to explore the combined use of different antimicrobial compounds in order 
to increase their efficacy. Biosurfactants-secondary metabolites produced by numerous 
microorganisms-have drawn attention of scientific community thanks to their interesting biological 
and chemical properties such as the ability to disturb cell membrane integrity and permeability and to 
affect adhesion of microorganisms [12]. In particular, lipopeptides are involved in the destabilization 
of membranes lipid packing. They penetrate into the membrane through hydrophobic interactions, 
influencing in the order of the hydrocarbon chain and varying the membrane thickness and form pores 
that change membrane permeability and decrease the cooperativity of lipid-lipid interactions [26–30]. 
Furthermore, lipopeptides are able to reduce the hydrophobicity of surfaces interfering with microbial 
adhesion and desorption processes [31]. 
In a previous work by the authors, it has been demonstrated that the lipopeptide biosurfactant 
AC7BS was characterized by antiadhesive activity against C. albicans planktonic and sessile cells [13]. 
Pre-treatment of silicone elastomeric disks with AC7BS caused the inhibition of fungal adhesion and 
biofilm formation without altering cell viability of both planktonic and sessile cells. Other studies 
successfully demonstrated the antiadhesive and anti-biofilm activity of lipopeptides against bacterial 
and fungal pathogens on polystyrene and silicone materials [32,33]. 
In the present study, for the first time, the association of AC7BS with two antifungal compounds 
extensively used in the treatment of invasive fungal infections, amphotericin B (AMB) and 
fluconazole (FLC), was explored on medical-grade silicone against planktonic and sessile cells of C. 
albicans 40, a clinical isolate from central venous catheter. Moreover, in order to emphasize the 
clinically oriented approach, the activity of AC7BS and antifungal agents, alone or in association, was 
assessed in the presence of fetal bovine serum, to mimic medical devices contact with biological fluids 
during clinical use in internal body areas. 
The evaluation of the anti-adhesive and anti-biofilm activity of AC7BS and antifungals was 
carried out in co-incubation and pre-coating conditions. Co-incubation assays were applied to assess 
AC7BS biological properties as adjuvant during antifungal treatments, as well as to measure its ability 
to dislodge pre-formed biofilms. On the other hand, pre-coating assays were used to evaluate the real 
efficacy and the possible applicability of AC7BS as medical devices coating agent for the prevention 
of microbial adhesion and biofilm formation, alone or in association to antifungal treatments. 
Antifungal agents were, generally, tested at three different concentrations: above the MIC, at MIC and 
at sub-MIC. The first two concentrations were tested with the objective of defining whether the 
lipopeptide could enhance the killing activity of the antifungal drug. The sub-MIC concentration was 
tested to assess whether the presence of AC7BS could determine an increase in the antifungal activity, 
with the consequent decrease of the MIC value. This combined activity could allow the reduction of 
the therapeutic dose of antifungal agent, thus limiting the occurrence of adverse reactions and the onset 
of resistances. 
In general, when AC7BS was used in association with AMB or FLC, a synergistic activity against 
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planktonic cells and biofilm formation was observed. The term synergism, meaning working together, 
is referred to the interaction between two or more molecules when their effect in association is greater 
than the combination of the effects of the individual compounds. 
In the case of planktonic cells, despite the inability of AC7BS to inhibit cells viability, the 
antifungal activity of AMB and FLC was synergistically increased by the presence of the biosurfactant 
and a reduction of MICs values was observed for both the antifungal agents.  
In anti-biofilm assays, in co-incubation experiments, results demonstrated a significant inhibitory 
effect of AMB against sessile cells. FLC affected the intermediate phase of biofilm formation but was 
unable to reduce 24 h-old biofilms. It was also observed that AC7BS alone was not able to inhibit 
sessile cells but, generally, it increased the killing activity of antifungal agents when used in 
association. In addition, a reduction of SMICs values was observed for AMB. 
It can be hypothesized that the antifungal activity of AMB or FLC is synergistically increased by 
the interaction of AC7BS with membrane lipids leading to a higher permeability of plasma membranes 
to antifungal agents.  
Another work described a synergistic effect of a lipopeptide in co-incubation with various 
antibiotics against biofilm of the uropathogenic strain E. coli CFT073 on polystyrene [14]. The 
combined use of V9T14 lipopeptide and six different antibiotics [cefazolin, ciprofloxacin, ceftriaxone, 
piperacillin, tobramycin and trimethoprim/sulfamethoxazole (SXT) (19:1)] led to a reduction of 
biofilms in terms of CFU ml–1 ranging from 1.0 log10 to 2.1 log10, whereas the association of the 
biosurfactant with ampicillin led to a complete eradication. Similarly to AC7BS, the presence of 
V9T14 did not affect cell viability of planktonic and sessile cells but decreased the amount of 
antibiotics required to obtain the same cell reduction detected with the antibiotic alone. 
In pre-coating experiments, the absorption of AC7BS on silicone disks resulted in a significant 
reduction of biofilm formation confirming the antiadhesive properties of this biosurfactant. The 
treatment with AMB alone showed a higher inhibitory effect when added after the adhesion phase. A 
less marked, but still significant, activity was observed when the antifungal agent was added directly to 
the fungal suspension and on 24-old biofilms.  Interestingly, when AC7BS and AMB were used in 
association, a synergistic activity of the two molecules against C. albicans 40 biofilm formation was 
observed. In particular, the most encouraging results were obtained in pre-coating type 2 experiments, 
wherein the co-use of AC7BS and AMB at all concentrations decreased biofilm formation of more 
than 90%. Furthermore, it was also possible to observe a reduction of the concentration of antifungal 
agent needed to achieve the SMICs values.  
In this case, the synergism can be due both to the anti-adhesive activity of AC7BS and to the 
antifungal effect of AMB, but also to the previously indicated ability of the biosurfactant to decrease 
the cooperativity of the lipid-lipid interactions in the bilayer membrane, thus facilitating the entry of 
AMB in the cells. 
5. Conclusion 
The study demonstrated, for the first time, that the association of lipopeptide AC7 with antifungal 
agents leads to a synergistic effect in inhibiting C. albicans 40 planktonic cells and biofilm formation. 
Although additional studies are required to determine the molecular basis of these observations, these 
results suggest that the joint activity of AC7BS and antifungal agents might have potential 
applicability in prophylactic or therapeutic strategy against C. albicans infections related to the use of 
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medical insertional materials. 
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